Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2590-2597

  Niska, Jared A ^a   Shahbazian, Jonathan H ^b   Ramos, Romela Irene ^b   Pribaz, Jonathan R ^a   Billi, Fabrizio ^a   Francis, Kevin P ^c   Miller, Lloyd S ^a,b  

^a JOINT REPLACEMENT INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PERKINELMER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; NOVAPLUS; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BIOFILM; BIOLUMINESCENCE; CONTROLLED STUDY; DEVICE INFECTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; IN VIVO STUDY; INFECTION PREVENTION; LOW DRUG DOSE; MALE; METAL IMPLANTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; COLONY COUNT, MICROBIAL; DAPTOMYCIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; KNEE PROSTHESIS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED C57BL; MINOCYCLINE; MODELS, ANIMAL; MOLECULAR IMAGING; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84860123825     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06291-11     Document Type: Article

References (50)

1. AlBuhairan B, Hind D, Hutchinson A. 2008. Antibiotic prophylaxis for wound infections in total joint arthroplasty: a systematic review. J. Bone Joint Surg. Br. 90:915-919. (Pubitemid 352009780)
2. Anderson DJ, et al. 2010. Variation in the type and frequency of postoperative invasive Staphylococcus aureus infections according to type of surgical procedure. Infect. Control Hosp. Epidemiol. 31:701-709.
3. Anderson DJ, et al. 2009. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PLoS One 4:e8305.
4. Anderson DJ, et al. 2008. Strategies to prevent surgical site infections in acute care hospitals. Infect. Control Hosp. Epidemiol. 29(Suppl.1):S51-S61.
5. Archer NK, et al. 2011. Staphylococcus aureus biofilms: Properties, regulation, and roles in human disease. Virulence 2:445-459.
6. Aslam S, Trautner BW, Ramanathan V, Darouiche RO. 2007. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob. Agents Chemother. 51:1556-1558. (Pubitemid 46586852)
7. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. 2005. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl. 5):S354-S367. (Pubitemid 41170382)
8. Baddour LM, et al. 2010. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 121:458-477.
9. Beiras-Fernandez A, Vogt F, Sodian R, Weis F. 2010. Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens. Infect. Drug Resist. 3:95-101.
10. Bolon MK, et al. 2004. Glycopeptides are no more effective than betalactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin. Infect. Dis. 38:1357-1363. (Pubitemid 38668578)
11. Cafiso V, Bertuccio T, Spina D, Purrello S, Stefani S. 2010. Tigecycline inhibition of a mature biofilm in clinical isolates of Staphylococcus aureus: comparison with other drugs. FEMS Immunol. Med. Microbiol. 59:466-469.
12. Darouiche RO. 2004. Treatment of infections associated with surgical implants. N. Engl. J. Med. 350:1422-1429. (Pubitemid 38419996)
13. Del Pozo JL, Patel R. 2009. Clinical practice. Infection associated with prosthetic joints. N. Engl. J. Med. 361:787-794.
14. de Oliveira JC, et al. 2009. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ. Arrhythm. Electrophysiol. 2:29-34.
15. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323. (Pubitemid 36368592)
16. Edmiston CE, Jr, et al. 2006. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am. J. Surg. 192:344-354.
17. Gander S, Kinnaird A, Finch R. 2005. Telavancin: in vitro activity against staphylococci in a biofilm model. J. Antimicrob. Chemother. 56:337-343. (Pubitemid 41158522)
18. Giacometti A, et al. 2005. Comparative efficacies of quinupristindalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. Antimicrob. Agents Chemother. 49:4042-4045. (Pubitemid 41400944)
19. Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2:95-108. (Pubitemid 39490064)
20. Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. 1987. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob. Agents Chemother. 31:393-397. (Pubitemid 17027127)
21. Hegde SS, et al. 2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob. Agents Chemother. 48:3043-3050. (Pubitemid 38989173)
22. John AK, et al. 2009. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53:2719-2724.
23. John AK, Schmaler M, Khanna N, Landmann R. 2011. Reversible daptomycin tolerance of adherent staphylococci in an implant infection model. Antimicrob. Agents Chemother. 55:3510-3516.
24. Kurtz SM, et al. 2008. Infection burden for hip and knee arthroplasty in the United States. J. Arthroplasty 23:984-991.
25. Lee J, et al. 2006. Surgical site infection in the elderly following orthopaedic surgery. Risk factors and outcomes. J. Bone Joint Surg. Am. 88:1705-1712. (Pubitemid 44200207)
26. Louie A, et al. 2001. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 45:845-851. (Pubitemid 32182035)
27. Matar WY, et al. 2010. Preventing infection in total joint arthroplasty. J. Bone Joint Surg. Am. 92(Suppl. 2):36-46.
28. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. 2005. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. 41(Suppl. 5):S333-S340. (Pubitemid 41170380)
29. Miller LG, McKinnell JA, Vollmer ME, Spellberg B. 2011. Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery. Infect. Control Hosp. Epidemiol. 32:342-350.
30. Olson MW, et al. 2006. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob. Agents Chemother. 50:2156-2166. (Pubitemid 43807538)
31. Pribaz JR, et al. 2012. Mouse model of chronic post-arthroplasty infection: noninvasive in vivo bioluminescence imaging to monitor bacterial burden for long-term study. J. Orthop. Res. 30:335-340.
32. Prokuski L. 2008. Prophylactic antibiotics in orthopaedic surgery. J. Am. Acad. Orthop. Surg. 16:283-293.
33. Raad I, et al. 2007. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. 51:1656-1660. (Pubitemid 46744141)
34. Reipert A, Ehlert K, Kast T, Bierbaum G. 2003. Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Antimicrob. Agents Chemother. 47:568-576. (Pubitemid 36158084)
35. Reyes N, et al. 2006. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:462-465. (Pubitemid 44294968)
36. Reyes N, et al. 2005. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:4344-4346. (Pubitemid 41400983)
37. Rosenberger LH, Politano AD, Sawyer RG. 2011. The surgical care improvement project and prevention of post-operative infection, including surgical site infection. Surg. Infect. (Larchmt.) 12:163-168.
38. Sakoulas G, Moellering RC, Jr, Eliopoulos GM. 2006. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 42(Suppl. 1):S40-S50. (Pubitemid 41832064)
39. Saliba R, Paasch L, El Solh A. 2009. Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines. Immunopharmacol. Immunotoxicol. 31:583-588.
40. Salvatore CM, et al. 2009. Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob. Agents Chemother. 53:1546-1551.
41. Smith K, et al. 2010. Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:380-387.
42. Stevens DL. 2006. The role of vancomycin in the treatment paradigm. Clin. Infect. Dis. 42(Suppl. 1):S51-S57. (Pubitemid 41832065)
43. Thurlow LR, et al. 2011. Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. J. Immunol. 186:6585-6596.
44. Uslan DZ, et al. 2007. Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch. Intern. Med. 167:669-675. (Pubitemid 46598459)
45. van Hal SJ, Paterson DL. 2011. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:405-410.
46. van Ogtrop ML, et al. 2000. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Grampositive and Gram-negative bacteria. Antimicrob. Agents Chemother. 44:943-949.
47. Weiss EC, Spencer HJ, Daily SJ, Weiss BD, Smeltzer MS. 2009. Impact of sarA on antibiotic susceptibility of Staphylococcus aureus in a catheter-associated in vitro model of biofilm formation. Antimicrob. Agents Chemother. 53:2475-2482.
48. Williams I, et al. 1999. Flow cytometry and other techniques show that Staphylococcus aureus undergoes significant physiological changes in the early stages of surface-attached culture. Microbiology 145(Pt 6):1325-1333. (Pubitemid 29294918)
49. Woodworth, Jr, Nyhart EH, Jr, Brier GL, Wolny JD, Black HR. 1992. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob. Agents Chemother. 36:318-325.
50. Zimmerli W, Sendi P. 2011. Pathogenesis of implant-associated infection: the role of the host. Semin. Immunopathol. 33:295-306.